Beijing Konruns Pharmaceutical Co., Ltd. Class ASSE: 603590

Announcement on KC1036 Obtaining CDE Approval for Pivotal Phase III Clinical Study in Advanced Thymic Carcinoma

· Issued by Beijing Konruns Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on KC1036 Obtaining CDE Approval for Pivotal Phase III Clinical Study in Advanced Thymic Carcinoma

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment